MicroRNAs as novel biomarkers and potential therapeutic options for inflammatory cardiomyopathy
- PMID: 37679968
- PMCID: PMC10682862
- DOI: 10.1002/ehf2.14523
MicroRNAs as novel biomarkers and potential therapeutic options for inflammatory cardiomyopathy
Abstract
Aims: Inflammation of the heart is a complex biological and pathophysiological response of the immune system to a variety of injuries leading to tissue damage and heart failure. MicroRNAs (miRNAs) emerge as pivotal players in the development of numerous diseases, suggesting their potential utility as biomarkers for inflammation and as viable candidates for therapeutic interventions. The primary aim of this investigation was to pinpoint and assess particular miRNAs in individuals afflicted by virus-negative inflammatory dilated cardiomyopathy (DCMi).
Methods and results: The study involved the analysis of 152 serum samples sourced from patients diagnosed with unexplained heart failure through endomyocardial biopsy. Among these samples, 38 belonged to DCMi patients, 24 to DCM patients, 44 to patients displaying inflammation alongside diverse viral infections, and 46 to patients solely affected by viral infections without concurrent inflammation. Additionally, serum samples from 10 healthy donors were included. The expression levels of 754 distinct miRNAs were evaluated using TaqMan OpenArray. MiR-1, miR-23, miR-142-5p, miR-155, miR-193, and miR-195 exhibited exclusive down-regulation solely in DCMi patients (P < 0.005). These miRNAs enabled effective differentiation between individuals with inflammation unlinked to viruses (DCMi) and all other participant groups (P < 0.005), boasting a specificity surpassing 86%.
Conclusions: The identification of specific miRNAs offers a novel diagnostic perspective for recognizing intramyocardial inflammation within virus-negative DCMi patients. Furthermore, these miRNAs hold promise as potential candidates for tailored therapeutic strategies in the context of virus-negative DCMi.
Keywords: Biomarker; Cardiomyopathy; Inflammation; MiRNA.
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Conflict of interest statement
None declared.
Figures



Similar articles
-
MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies.ESC Heart Fail. 2021 Feb;8(1):408-422. doi: 10.1002/ehf2.13090. Epub 2020 Nov 20. ESC Heart Fail. 2021. PMID: 33215881 Free PMC article.
-
Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.Herz. 2004 Sep;29(6):624-36. doi: 10.1007/s00059-004-2628-7. Herz. 2004. PMID: 15912438 Review.
-
Discovery of miRNAs unique to actively transcribed erythroparvovirus infection in heart failure patients.ESC Heart Fail. 2025 Jun;12(3):1872-1882. doi: 10.1002/ehf2.15194. Epub 2025 Feb 19. ESC Heart Fail. 2025. PMID: 39970057 Free PMC article.
-
Circulating microRNAs as novel biomarkers for dilated cardiomyopathy.Cardiol J. 2017;24(1):65-73. doi: 10.5603/CJ.a2016.0097. Epub 2016 Oct 17. Cardiol J. 2017. PMID: 27748501
-
Inflammatory dilated cardiomyopathy (DCMI).Herz. 2005 Sep;30(6):535-44. doi: 10.1007/s00059-005-2730-5. Herz. 2005. PMID: 16170686 Review.
Cited by
-
Cardiomyopathies: The Role of Non-Coding RNAs.Noncoding RNA. 2024 Oct 23;10(6):53. doi: 10.3390/ncrna10060053. Noncoding RNA. 2024. PMID: 39449507 Free PMC article. Review.
-
Obesity and 1-year all-cause survival of adult intensive care patients with heart failure: data from the MIMIC-IV.Diabetol Metab Syndr. 2024 Aug 7;16(1):190. doi: 10.1186/s13098-024-01428-3. Diabetol Metab Syndr. 2024. PMID: 39113062 Free PMC article.
-
Serum levels of miR-21, miR-23a, miR-142-5p, and miR-126 in chronic failure with reduced ejection fraction: a case-control study.Front Cardiovasc Med. 2025 May 15;12:1529451. doi: 10.3389/fcvm.2025.1529451. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40443967 Free PMC article.
-
The Role of MicroRNA in the Pathophysiology and Diagnosis of Viral Myocarditis.Int J Mol Sci. 2024 Oct 11;25(20):10933. doi: 10.3390/ijms252010933. Int J Mol Sci. 2024. PMID: 39456716 Free PMC article. Review.
-
Recent advances of miR-23 in human diseases and growth development.Noncoding RNA Res. 2024 Dec 30;11:220-233. doi: 10.1016/j.ncrna.2024.12.010. eCollection 2025 Apr. Noncoding RNA Res. 2024. PMID: 39896346 Free PMC article. Review.
References
-
- Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:2648a‐2648d. doi:10.1093/eurheartj/eht210 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical